Tyra Biosciences, Inc. holdings disclosed by Janus Henderson Group plc via an amended Schedule 13G/A reporting 3,890,589 common shares, representing 7.2% of the class. The filing states the Asset Managers exercise shared voting and dispositive power over these shares.
The disclosure clarifies the Asset Managers act on behalf of Managed Portfolios and disclaim rights to receive dividends or sale proceeds; signature dated 5/15/2026.
Positive
None.
Negative
None.
Insights
Large passive holding disclosed: shared control of 3,890,589 shares (7.2%).
The filing shows Janus Henderson Group plc as the parent of multiple Asset Managers that collectively exercise voting/dispositive discretion over 3,890,589 shares. The ownership is reported as shared power, not sole control, and is tied to Managed Portfolios.
Implications depend on how the various Asset Managers allocate votes across clients; subsequent Form 13 filings could detail any voting coordination or changes in percent ownership.
Disclosure emphasizes agency relationships and voting discretion, not economic receipt rights.
The statement disclaims rights to dividends or sale proceeds by the Asset Managers while explaining they exercise investment and voting discretion for client accounts. This distinguishes beneficial voting/dispositive power from direct economic ownership.
Watch for any amendments or exhibits that identify specific subsidiaries or client accounts referenced in Item 7 and Exhibit 99 for further allocation details.
Key Figures
Shares reported:3,890,589 sharesPercent of class:7.2%Shared voting power:3,890,589 shares+3 more
6 metrics
Shares reported3,890,589 sharesAmount beneficially owned by Asset Managers
Percent of class7.2%Percent of Tyra Biosciences common stock
Shared voting power3,890,589 sharesShared power to vote or direct the vote
Shared dispositive power3,890,589 sharesShared power to dispose or direct disposition
CUSIP90240B106Tyra Biosciences, Inc. common stock identifier
Signature date5/15/2026Date of filing signature by compliance officer
Key Terms
Beneficially owned, Managed Portfolios, Shared dispositive power
3 terms
Beneficially ownedregulatory
"may be deemed to be the beneficial owner of 3,890,589 common stock"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Managed Portfoliosfinancial
"clients which include investment companies, other investment advisers, institutional separate accounts"
Shared dispositive powerregulatory
"Shared power to dispose or to direct the disposition of: 3890589"
What stake does Janus Henderson Group plc report in TYRA?
Janus Henderson reports 3,890,589 shares, equal to 7.2% of Tyra Biosciences' common stock, held by its Asset Managers across Managed Portfolios and disclosed on the Schedule 13G/A.
Does Janus Henderson claim economic rights to dividends or sale proceeds for these TYRA shares?
The filing states the Asset Managers do not have the right to receive dividends or sale proceeds from the securities held in the Managed Portfolios, and disclaim ownership associated with such rights.
What voting and dispositive powers are reported by Janus Henderson over TYRA shares?
The filing reports shared voting power of 3,890,589 shares and shared dispositive power of 3,890,589, with no sole voting or dispositive power claimed.
Are any Managed Portfolios individually over 5% of TYRA according to the filing?
The filing states that, of the Managed Portfolios, none own more than five percent of Tyra Biosciences' common stock, while the aggregate managed stake totals 7.2%.
When was the Schedule 13G/A signed and who signed it?
The amendment is signed by Kristin Mariani, Head of North America Compliance, with signature date listed as 5/15/2026 on the filing.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
TYRA BIOSCIENCES, INC
(Name of Issuer)
Common Stock
(Title of Class of Securities)
90240B106
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
JANUS HENDERSON GROUP PLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
JERSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,890,589.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,890,589.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,890,589.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.2 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
TYRA BIOSCIENCES, INC
(b)
Address of issuer's principal executive offices:
2656 STATE STREET
CARLSBAD, CA 92008
Item 2.
(a)
Name of person filing:
Janus Henderson Group plc
(b)
Address or principal business office or, if none, residence:
201 Bishopsgate
EC2M 3AE, United Kingdom
(c)
Citizenship:
Y9
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
90240B106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Janus Henderson Group plc (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, and Victory Park Capital Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 3,890,589 common stock of Tyra Biosciences, Inc. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
(b)
Percent of class:
7.2 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
3890589
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
3890589
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts.
Of the Managed Portfolios, none own more than five percent of the common stock of Tyra Biosciences, Inc.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please refer to Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
N/A
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
